| Literature DB >> 36078645 |
Mary-Magdalene Osei1,2, Nicholas T K D Dayie1, Godfred S K Azaglo3, Elizabeth Y Tettey4, Edmund T Nartey5, Ama P Fenny6, Marcel Manzi7, Ajay M V Kumar8,9,10, Appiah-Korang Labi11, Japheth A Opintan1, Eric Sampane-Donkor1.
Abstract
Nasopharyngeal carriage of aerobic Gram-negative bacilli (GNB) may precede the development of invasive respiratory infections. We assessed the prevalence of nasopharyngeal carriage of aerobic GNB and their antimicrobial resistance patterns among healthy under-five children attending seven selected day-care centres in the Accra metropolis of the Greater Accra region of Ghana from September to December 2016. This cross-sectional study analysed a total of 410 frozen nasopharyngeal samples for GNB and antimicrobial drug resistance. The GNB prevalence was 13.9% (95% CI: 10.8-17.6%). The most common GNB were Escherichia coli (26.3%), Klebsiella pneumoniae (24.6%), and Enterobacter cloacae (17.5%). Resistance was most frequent for cefuroxime (73.7%), ampicillin (64.9%), and amoxicillin/clavulanic acid (59.6%). The organisms were least resistant to gentamicin (7.0%), amikacin (8.8%), and meropenem (8.8%). Multidrug resistance (MDR, being resistant to ≥3 classes of antibiotics) was observed in 66.7% (95% CI: 53.3-77.8%). Extended-spectrum beta-lactamase (ESBL)-producing bacteria constituted 17.5% (95% CI: 9.5-29.9%), AmpC-producing bacteria constituted 42.1% (95% CI: 29.8-55.5%), and carbapenemase-producing bacteria constituted 10.5% (95% CI: 4.7-21.8%) of isolates. The high levels of MDR are of great concern. These findings are useful in informing the choice of antibiotics in empiric treatment of GNB infections and call for improved infection control in day-care centres to prevent further transmission.Entities:
Keywords: AmpC; Gram-negative bacilli (GNB); Structured Operational Research and Training Initiative (SORT IT); carbapenemase; extended-spectrum beta-lactamases (ESBL); nasopharyngeal carriage prevalence; operational research; resistant pathogenic bacteria
Mesh:
Substances:
Year: 2022 PMID: 36078645 PMCID: PMC9518304 DOI: 10.3390/ijerph191710927
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Prevalence of aerobic Gram-negative bacteria (by age, sex, and district) isolated from the nasopharynx of healthy under-five children in Accra, Ghana, from September to December 2016.
| Number of | Prevalence of GNB | ||||
|---|---|---|---|---|---|
| N | (%) | ||||
|
| 410 | 57 | (13.9) | ||
|
| Male | 210 | 26 | (12.3) | 0.36 |
| Female | 200 | 31 | (15.5) | ||
|
| ≤12 | 5 | 2 | (40.0) | 0.20 |
| 13–24 | 56 | 10 | (17.8) | ||
| 25–36 | 172 | 24 | (13.9) | ||
| 37–48 | 129 | 14 | (10.8) | ||
| 49–60 | 48 | 7 | (14.5) | ||
|
| Ashiedu Keteke | 217 | 34 | (15.7) | 0.53 |
| Okaikoi South | 55 | 7 | (12.7) | ||
| Ablekuma south | 138 | 16 | (11.6) | ||
Aerobic Gram-negative bacteria isolated from the nasopharynx of healthy under-five children in Accra, Ghana, from September to December 2016.
| Bacteria Isolated | Number | (%) |
|---|---|---|
| Total isolates | 57 | (100) |
|
| 15 | (26.3) |
|
| 14 | (24.6) |
|
| 10 | (17.5) |
|
| 5 | (8.9) |
|
| 4 | (7.0) |
|
| 3 | (5.3) |
|
| 3 | (5.3) |
|
| 2 | (3.5) |
|
| 1 | (1.8) |
Figure 1Antibiotic resistance pattern of aerobic Gram-negative bacteria isolated from the nasopharynx of healthy under-five children in Accra, Ghana, from September to December 2016.
Percentages of MDR and ESBL-, AmpC-, and carbapenemase-producing bacteria isolated from the nasopharynx of healthy under-five children in Accra, Ghana, from September to December 2016.
| Bacteria Isolated | Number | MDR | ESBL- | AmpC- | Carbapenemase-Producing % |
|---|---|---|---|---|---|
| Total | 57 | 66.7 | 17.5 | 42.1 | 10.5 |
|
| 15 | 80.0 | 33.3 | 26.7 | 20.0 |
|
| 14 | 57.1 | 21.4 | 28.6 | 7.1 |
|
| 10 | 90.0 | 0.0 | 0.0 | - |
|
| 5 | 100.0 | 20.0 | 100.0 | 20.0 |
|
| 4 | 25.0 | 0.0 | 0.0 | 0.0 |
| 3 | 0.0 | 0.0 | 0.0 | - | |
|
| 3 | 66.7 | 33.3 | 33.3 | - |
|
| 2 | 50.0 | 0.0 | 50.0 | - |
|
| 1 | 0.0 | 0.0 | 0.0 | - |
MDR = multidrug resistance; ESBL = extended-spectrum beta lactamase.